Clinical trial
Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT00079456 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00079456 |
|---|---|
| Title | Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma |
| Official title | A Phase II Trial of CCI-779 in Patients With Relapsed or Refractory Multiple Myeloma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma |
| Intervention type | Drug, Other |
| Interventions | temsirolimus, pharmacological study, laboratory biomarker analysis |
| Enrollment | 25 |
| Start date | Feb 1, 2004 |
| Primary completion | Feb 1, 2007 |
| First posted | Mar 10, 2004 |
| Last update posted | Oct 11, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: